What has been the rhetoric from Harvey,
in regards to a '534 partnership? I know in the past he has said (as far back as a year ago), they are actively looking for a partner.
"In reality the balance sheet has never looked better with funding sufficient into 2H11"
I disagree. Assuming the capital markets continue to be volatile, I do not want to see my stock diluted (again) at these levels. Around the 1st quarter of next year, if Ariad has not received funding and if the SUCCEED trial is a negative, investors are going to be focused on one thing and one thing alone: funding. The albatross on Ariad's neck for the past 2 years has been funding. I am sick and tired of it....and I think the recent Merck re-neg lessens that and gives us more time.
I would think that $80 million would be enough for a lot of stuff now that Merck has all the costs of Rida going forward, but it seems like Harvey is stating they are going to blow through that very quickly.
I want to be in a very viable position. A position of having a couple hundred million dollars: 1. For '113 quick advancement (I think if Ariad had money last year, we would already have an IND), and 2. For full funding of '534 in AML and solid tumors (something Harvey said would be happening 2 years ago - that is, starting trials in solid tumors).
I want to see them sign a deal worth $100 million for '534 ex-USA sales. Incyte and other companies have signed deals similar, I do not see why Ariad cannot.
News 
Market Data 
Discover 
